About the Authors

Ian J. Douglas

ian.douglas@lshtm.ac.uk

Affiliation Non Communicable Disease Unit, Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Stephen J. Evans

Affiliation Medical Statistics Unit, Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Stuart Pocock

Affiliation Medical Statistics Unit, Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Liam Smeeth

Affiliation Non Communicable Disease Unit, Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Competing Interests

IJD consults for and holds stock in GlaxoSmithKline. SJE is a co-opted member of the Pharmacovigilance Working Party at the European Medicines Agency (EMEA) and therefore advises on issues of drug safety relevant to Europe. SP consults for GlaxoSmithKline and is on the steering committee of the RECORD rosiglitazone study. LS reports no conflicts of interest.

Author Contributions

ICMJE criteria for authorship read and met: ID SE SP LS. Agree with the manuscript's results and conclusions: ID SE SP LS. Designed the experiments/the study: ID SE SP LS. Analyzed the data: ID SE. Wrote the first draft of the paper: ID. Contributed to the writing of the paper: SE SP LS. Contributed to the interpretation: SE SP.